Zydus bags rights to market MonoFerric injection in India, Nepal from Pharmacosmos A/S of Denmark

Zydus Lifesciences Ltd has acquired rights to market MonoFerric injection, used to treat iron deficiency in adult patients, in India and Nepal from Denmark-based Pharmacosmos A/S, the company said in a stock exchange filing on Friday.

MonoFerric is indicated to treat iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly. The financial details of the transaction have not been disclosed.

The MonoFerric iron isomaltoside 1,000 solution for injection/infusion, is a rapid, single dose IV iron (up to 20 mg/kg bodyweight) developed to reduce the number of infusions required to achieve iron correction.


The company said MonoFerric is available in over 30 countries including the US and Europe and over 28 million doses have been administered since launch.

Iron Deficiency is a severe healthcare challenge and also impacts the quality of life more so in CKD (chronic kidney disease) patients, Zydus Lifesciences Managing Director Dr Sharvil Patel said. Patients will now get access to this critical therapy which will be enhanced by the company's "strong last-mile delivery".